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INTRODUCTION
The incidence of diabetes and hypertension 
has risen sharply in sub- Saharan Africa along-
side a continuing high burden of HIV infec-
tion.1 In many settings, the prevalence figures 
among adults are 4%–5% for diabetes, above 
25% for hypertension and 5%–20% for HIV 
infection.2–4 All these conditions require 
lifelong treatment, and they have increased 
substantially the demand for chronic care 
services in Africa, where health systems have, 
until recently, focused on tackling acute infec-
tious diseases.5
There is considerable inequity in service 
provision for chronic diseases. HIV services, 
including antiretroviral therapy, are available 
widely for free and are organised typically in 
stand- alone clinics. Over 65% of people esti-
mated to be living with HIV infection are in 
regular care.6 In contrast, this figure is only 
about 5%–20% for people living with diabetes 
or hypertension.3 7 A major challenge is that 
medicines for diabetes and hypertension are 
generally not provided free of charge and 
have to be purchased by patients. Even in 
those countries that do provide free medicines 
for hypertension and diabetes, shortages are 
common and patients then have to purchase 
the medicines from private suppliers.
Our research collaboration is evaluating a 
biomedical diabetes preventive intervention in 
people living with HIV infection in a placebo- 
controlled randomised trial and, separately, 
evaluating integrated healthcare provision 
compared with standard care for people living 
with HIV, diabetes or hypertension in a cluster- 
randomised controlled trial.8 There are no data 
on the effectiveness of these approaches from 
Africa. Therefore, these trials have clinical and 
health economic endpoints and the research is 
underpinned by an implementation research 
approach, which, for example, requires strong 
engagement with health policy makers .9–12
We discuss the implications of a limited 
supply of medicines and potential solutions 
to track the equity of medicine supply. In 
particular, we consider what should the ethical 
approach be for a research programme in 
terms of provision of a steady and sustainable 
supply of medicines for patients with diabetes 
and hypertension when alternative affordable 
and accessible supplies are unavailable?
POSSIBLE SOLUTIONS AND LESSONS FROM 
OTHER CONTEXTS
Should the research be conducted in real-
world conditions where medicines supply for 
hypertension and diabetes is patchy?
If we conduct the research within the context 
of real- world conditions, then, under the 
Summary box
 ► Conducting intervention studies in Africa, where 
medicines supply for chronic conditions is inequita-
ble and patchy, raises major ethical issues.
 ► Here we discuss what should the ethical approach 
be for a research programme in terms of provision 
of a steady and sustainable supply of medicines for 
patients with diabetes and hypertension.
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integrated care model that we are testing, patients with 
different conditions would sit together in the same 
clinic and have consultations with the same healthcare 
providers. It will be morally challenging for clinical 
staff and researchers to turn away one group of patients 
because of a lack of medicines while for others, with HIV 
infection, treatment is available freely. In the past, in the 
vertical stand- alone models of care, the ethical dilemma 
was less stark because HIV and diabetes/hypertension 
clinics operated at different locations, sometimes on 
different days and involved different clinicians.
As well as the issue of inequity, observing people living 
with diabetes and hypertension unable to access medi-
cines, which are both low- cost and effective, could break 
the ethical principle of beneficence, which states that 
researchers should have the welfare of the participants 
as a goal.12
Also, if the research is conducted to real- world condi-
tions, it may be of limited relevance by the time it is 
completed. This is because the provision of medicines 
for chronic disease management in Africa is likely to 
increase in the next few years with the increased pressure 
that is now on donors and governments to support these 
treatment programmes. If drug shortages decrease, then 
the findings of our research programme, which would be 
available in a few years’ time, would be of very limited 
relevance when they are published.
Thus, in our view, there are both moral and scientific 
reasons for ensuring patients entering such intervention 
studies have access to uninterrupted supplies of medi-
cines for the duration of the research.
Should the research programme purchase the medicines for 
participants to enable the research to run smoothly?
If the study identifies a model of care that is cost- 
effective, it could give impetus to government health 
services to strengthen their medicine supply chains. On 
the contrary, by carrying the cost that should be met by 
governments and donors, it could potentially reduce the 
pressure on health authorities to find solutions, weaken 
the advocacy for patients’ rights and inhibit the public 
from demanding their rights to access treatments. Advo-
cacy for the right to access antiretroviral therapy was 
crucial in HIV control in Africa13 and will likely play a 
major role in enhancing access to medicines for diabetes 
and hypertension.
If the research programme provides the medicines for 
study participants, it would not be sustainable beyond 
the duration of the research programme and would 
mean that patients who access treatment services today 
may have to stop taking their medicines when the study 
finishes. While the study is running, provision of free 
drugs would be a strong incentive for participants to join 
the study. Patients will have the right to decline and to 
receive the care they would otherwise have received, but 
if this means a less reliable supply of medicines (than in 
the research programme), then patients are very likely 
to join the research. The issue is whether or not this is 
undue coercion.
In our view, the ideal situation here is that access to 
medicines is strengthened for all, ideally by Ministries of 
Health. For this to happen, researchers must work in part-
nership with policy makers and disease control managers, 
that is, policy makers and disease control managers must 
have ownership of the research. Researchers should be 
prepared to purchase medicines for short- term use to 
cover any gaps that might occur. Where Ministries of 
Health cannot achieve a reliable supply, even with the 
support of research programmes, then research in those 
settings may not be feasible.
Is there an obligation to provide medicines to non-trial 
participants?
Another ethical dilemma arises because the research 
programme will include only a fraction of all the patients 
with the target conditions attending the clinics and 
patients not in the research studies will not have access to 
any enhanced treatment. Although the costs of treatment 
for diabetes and hypertension are relatively low, it is most 
unlikely that a research programme could bear the costs 
of treating large numbers of non- study participants and 
a requirement to do so would make the research non- 
viable.
Not providing medicines to non- study participants will 
cause inequity between patients in the trial and those 
who are not. It could compromise outcomes if partici-
pants share their medicines to spread the benefits, for 
example, with relatives with chronic conditions not in the 
study. It may also endanger community support for the 
study if this sends the message that we do not care about 
family members.
There is no precedence with provision of drugs to 
large numbers of non- study participants. When combi-
nation antiretroviral therapy for HIV was introduced 
in high- income countries, it was not available in public 
health clinics in Africa because of its high cost. Research 
in Africa at that time will have faced similar dilemmas 
but wide- scale provision only occurred more recently. At 
that time, there were also some calls that the standards in 
clinical trials around treatment and access to medicines 
should be the same in Africa as in high- income coun-
tries.14 However, the standardisation would have inhibited 
HIV research in Africa and was opposed by global health 
researchers.15 This enabled the research to be conducted 
quickly and at relatively low cost, and research on the 
prevention and management of diabetes and hyperten-
sion may need similar considerations. Thus, although not 
ideal, priority of medicines for research subjects will be 
essential in some settings where the supply of medicines 
cannot be strengthened for all.
Should the health facilities be encouraged to procure a 
greater supply of medicines to facilitate the research?
In some circumstances, health facilities might be able to 
procure a greater supply of medicines to facilitate the 
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research. In countries such as Tanzania and Uganda, 
under district fiscal decentralised systems, health facili-
ties have flexibility in how they spend their resources.
However, if the supply of medicines for diabetes and 
hypertension was augmented in this way, this could be 
at the expense of service provision for other conditions, 
raising further ethical concerns. Moreover, there are 
clear ethical issues if health facilities procure medicines 
to support a research programme without ensuring that 
this supply will be maintained after the study.
The ideal solution here is that health facilities are 
supported to strengthen all medicines supply, not just for 
diabetes and hypertension.
CONCLUSION
Research to inform strategies for the prevention and 
management of diabetes and hypertension is vital in 
Africa. However, such research raises complex ethical 
issues relating to the limited supply of medicines and 
a pragmatic approach specific to the African context is 
needed.
It is clear that the research would likely produce mean-
ingless results if the supply of medicines was erratic, but 
equally, the research programme cannot just purchase the 
necessary drugs for its trial participants. A solution to this 
conundrum has to be through discussion and working in 
partnership with the key stakeholders: the policy makers, 
disease control managers, healthcare providers, patient 
groups and community representatives. Indeed, a funda-
mental ethical requirement is meaningful engagement 
with the key stakeholders.10 11
Similar issues arose in the early years of research on 
HIV treatment in Africa when antiretroviral therapy was 
prohibitively expensive and not available widely. The 
research that was conducted in these situations precipi-
tated later pressure on the international community to 
ensure that life- saving medicines were made freely avail-
able to people living with HIV. HIV care and prevention 
would not have reached its current level without over-
coming the initial obstacles to research on treatment. 
There is a pressing need to take on board the lessons 
from the progress made with HIV control to develop and 
expand research on diabetes and hypertension control.
We have used our studies on three specific diseas-
es—HIV infection, diabetes and hypertension—to high-
light the ethical dilemmas, but the ethical challenges are 
likely to be common to other diseases.
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